Literature DB >> 5427500

Combination chemotherapy in generalized Hodgkin's disease.

W M Nicholson, M E Beard, D Crowther, A G Stansfeld, C P Vartan, J S Malpas, G H Fairley, R B Scott.   

Abstract

Fifty-two patients with generalized Hodgkin's disease were treated with a combination of mustine hydrochloride, vinblastine, procarbazine, and prednisolone. Complete remissions were obtained initially in six out of seven patients (86%) who had previously received no treatment, in 15 out of 19 (79%) who had had only radiotherapy in the past, and in 9 out of 26 (35%) who had previously been given chemotherapy with or without radiotherapy. Of these 30 patients in whom a complete remission was obtained 22 have been free of any symptoms or signs of disease for periods ranging from 4 to 22 months. The response to treatment was rapid, and toxicity was not a major problem, except in those who had previously been treated with cytotoxic drugs used continuously and not in courses. A comparative trial of radiotherapy and combination therapy in the treatment of Stage III Hodgkin's disease is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5427500      PMCID: PMC1701007          DOI: 10.1136/bmj.3.5713.7

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  COMBINED VINBLASTINE AND CHLORAMBUCIL THERAPY OF HODGKIN'S DISEASE.

Authors:  M J LACHER; J R DURANT
Journal:  Ann Intern Med       Date:  1965-03       Impact factor: 25.391

2.  A study of Hodgkin's disease treated by irradiation.

Authors:  M V PETERS; K C MIDDLEMISS
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1958-01

3.  Factors influencing survival in patients with Hodgkin's disease.

Authors:  D W Smithers
Journal:  Clin Radiol       Date:  1969-04       Impact factor: 2.350

4.  The pathology and nomenclature of Hodgkin's disease.

Authors:  R J Lukes; J J Butler
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

5.  Hodgkin's disease. Combined clinical staff conference at the National Institutes of Health.

Authors:  S Perry; L B Thomas; R E Johnson; P P Carbone; H A Haynes
Journal:  Ann Intern Med       Date:  1967-08       Impact factor: 25.391

6.  [Treatment of Hodgkin's disease by polychemotherapy combining nitrogen mustard, vincristine, methylhydrazine and prednisone].

Authors:  J Bernard; M Boiron; A Goguel; C Jacquillat; J Tanzer; M Weil
Journal:  Presse Med       Date:  1967-12-09       Impact factor: 1.228

  6 in total
  23 in total

Review 1.  [Hodgkin's disease. Results in diagnosis and treatment (author's transl)].

Authors:  D Huhn; W Wilmanns
Journal:  Klin Wochenschr       Date:  1979-04-17

Review 2.  [Diagnostic and therapeutic procedures in Hodgkin's disease].

Authors:  D Huhn; C Steidle
Journal:  Blut       Date:  1973-08

Review 3.  Antineoplastic and immunosuppressive drugs. II. Therapeutic uses.

Authors:  M D Cridland
Journal:  Drugs       Date:  1972       Impact factor: 9.546

4.  Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.

Authors:  J A Green; A A Dawson; L F Fell; S Murray
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

5.  [A modified MOPP regimen in the treatment of Hodgkin's disease stage III B and IV (author's transl)].

Authors:  F J Tigges; E Hiller; R M Schmülling; H D Waller; K Wilms
Journal:  Blut       Date:  1978-08-15

6.  If I had Hodgkin's disease.

Authors:  R A Wood
Journal:  Br Med J       Date:  1978-05-20

7.  Long-Term Survival Rates of Patients with Stage III-IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984-2013.

Authors:  Yushi Li; Huanhuan Sun; Yan Yan; Tiantian Sun; Shuncong Wang; Haiqing Ma
Journal:  Oncologist       Date:  2018-05-08

8.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 9.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Binding of vinblastine to recrystallized human alpha 1-acid glycoprotein.

Authors:  W H Steele; D J Haughton; H E Barber
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.